AstraZeneca and Eli Lilly and Co. said recently they will expand their present immuno-oncology collaboration to develop innovative combination therapy options for patients with solid tumors. Read More »

AstraZeneca said the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) about the new drug application (NDA) for the investigational fixed-dose combination of saxagliptin and dapagliflozin. The fixed-dose combination of saxagliptin and dapagliflozi is intended for the treatment of adult patients with Type 2 diabetes.  The CRL said more clinical data is required to support NDA. Read More »

AstraZeneca said Sept. 3 that the U.S. Food and Drug Administration has approved Brilinta (ticagrelor) tablets at a new 60 mg dose to be used in patients with a history of heart attack after the first year. Read More »

AstraZeneca recently announced a collaboration agreement with Valeant Pharmaceuticals International Inc., under which it will grant an exclusive license for Valeant to develop and commercialize brodalumab. Read More »

Diplomat Pharmacy Inc. on Monday announced it will offer IRESSA (gefitinib), which was recently approved by the U.S. Food and Drug Administration, as a first-line therapy for a specific type of metastatic non-small cell lung cancer. Read More »

AstraZeneca yesterday announced that Pam Cheng is now executive vice president of operations, with global responsibilities that include manufacturing operations, supply chain, procurement and information technology. Read More »

Incyte Corporation and Eli Lilly and Company recently announced that its investigational medicine baricitinib proved superior to the placebo that was used in the Phase 3 trial study for rheumatoid arthritis. The Phase 3 study involved over 3,000 subjects. Read More »

Under a final agreement between AstraZeneca and Actavis, AstraZeneca will procure the rights to Actavis’ proprietary respiratory business in the United States and Canada, the two companies announced on Feb. 5. Read More »

Incycte Corporation's recent clinical trial of Jakafi (ruxolitinib) found that the drug considerably reduced spleen volume while improving hematocrit control in patients with uncontrolled polycythemia vera (PV), a rare type of blood cancer. Read More »